Hans Biomed KRX:042520KOSDAQ
한스바이오메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked14since Sep 11
In Q2 2026, Hans Biomed reported revenue of ₩36.3bn, up 65.0% year on year, and operating profit of ₩4.1bn. Hans Biomed (한스바이오메드) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Screener
Hans Biomed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩36.3bn | +65.0% | ₩4.1bn margin 11.3% | ₩1.8bn |
| Q1 2026 | ₩34.5bn | +42.8% | ₩4.4bn margin 12.9% | ₩3.7bn |
| Q4 2025 | ₩30.3bn | +52.3% | ₩2.1bn margin 6.8% | ₩1.9bn |
| Q3 2025 derived | ₩23.7bn | +21.6% | −₩27.0bn margin −113.6% | −₩27.9bn |
| Q2 2025 | ₩22.0bn | +5.9% | ₩41m margin 0.2% | −₩3.4bn |
| Q1 2025 | ₩24.2bn | +18.1% | ₩1.8bn margin 7.3% | ₩729m |
| Q4 2024 | ₩19.9bn | – | −₩749m margin −3.8% | −₩2.0bn |
| Q3 2024 derived | ₩19.5bn | +2.6% | −₩1.1bn margin −5.4% | −₩6.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Hans Biomed top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Hans Biomed news Korean headlines
-
한스바이오메드, 에이템즈 지분 늘리는 이유…‘A-Paste-C’ 가치는
1 more on this story · 1 outlets
- 한스바이오메드, 에이템즈 지분 늘리는 이유…‘A-Paste-C’ 가치는이데일리 · Sep 21 07:31